Novartis V. Union of India & Others – A Landmark Judgement on Indian Patent Law & Pharmaceutical Industry: A Report The Supreme Court judement on the Novartis v. Union of India & Others is a landmark decision on the issue of pharmaceutical patent in India. The decision taken after a seven year long litigation fought by pharmaceutical major Novartis is based on a case pertaining to grant of Indian patent on a compound called Imatinib Mesylate in Beta Crystalline Form (referred as Imatinib hereinafter
Words: 2339 - Pages: 10
PFIZER An industry leader, an HR leader, too? November 2011 EXECUTIVE SUMMARY Pfizer, one of the global leaders in pharmaceutical industry, has also been recognized as one of the most admired companies in terms of both business and HR level. In organization’s official site, Pfizer advocates that a great amount of its achievements resides on the importance placed on fulfilling its mission and values, as well as on its dedication to hire, retain and inspire its employees by offering
Words: 1761 - Pages: 8
57 Company Reliance Industries Limited Tata Consultancy Services (TCS) Infosys Technologies Ltd Wipro Limited Bharti Tele-Ventures Limited ITC Limited Hindustan Lever Limited ICICI Bank Limited Housing Development Finance Corp. Ltd. TATA Steel Limited Ranbaxy Laboratories Limited HDFC Bank Ltd Tata Motors Limited Larsen & Toubro Limited (L&T) Satyam Computer Services Ltd. Maruti Udyog Limited Bajaj Auto Ltd. HCL Technologies Ltd. Hero Honda Motors Limited Hindalco Industries Ltd Reliance Energy Limited
Words: 2235 - Pages: 9
Pharmaceuticals Industry in India: Overview: Indian pharmaceutical sector accounts for about 2.4 per cent of the global pharmaceutical industry in value terms and 10 per cent in volume terms and is expected to expand at a Compound Annual Growth Rate (CAGR) of 15.92 per cent to US$ 55 billion by 2020 from US$ 20 billion in 2015. With 71 per cent market share, generic drugs form the largest segment of the Indian pharmaceutical sector. By 2016, India is expected to be the third-largest global generic
Words: 1727 - Pages: 7
MODEL (A) Current global market research indicates a significant growth of pharmaceutical products, in spite of the sluggish economy in 2010. The forecast indicated market growth of about 4% to 6% in 2010 exceeding US$ 825 Billion. The global pharma market will experience 5% to 7% growth in 2011 resulting in an overall market value of US$ 880 Billion. Asia Pacific Pharmaceutical Market is expected to grow around 12.6% during 2010 – 2012. Middle East – African Pharma Market is projected to
Words: 643 - Pages: 3
parts of Malaysia, Vietnam, Myanmar, Bangladesh, Indonesia and Philippines. The company has the core competency in making generic drugs for the entire nation. However, with the entry of the large global multinationals in the region like UK based Glaxo Smithkline, Germany based Novartis, India based Sun Pharma, China based Hepa link Pharmaceutical etc., the company started facing difficulty. From 1973 till 1990, the business of Health line grew at the rate of 23% on an average per year, which increased
Words: 1112 - Pages: 5
Medical Technology MEDICAL TECHNOLOGY VOL ATILE INDUSTRIES? A SAFE HAVEN for Novumed Spotlight Novumed Spotlight Novumed Spotlight The Benefit of Expansion into Medical Technology financial crisis 2008 2009 2010 2011 Segment comparison at Agilent 2008 - 2011, in US$ M. Source: Agilent annual reports, Novumed Life Science Consulting In 1999, several business units were spun off from global computer technology provider HewlettPackard to form Agilent, with approx
Words: 3838 - Pages: 16
one of the most established companies in the Indian and Global pharmaceutical industry. DRL is a 200 million dollar venture with presence in almost all major therapeutic areas, providing affordable and innovative medicines in all major therapeutic areas like gastro-intestinal, oncology, pain management, cardiovascular, dermatology, diabetes, etc. DRL operates in three business segments- Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products. Its Indian manufacturing
Words: 4430 - Pages: 18
Dhaka Stock Exchange. Square Pharmaceuticals Ltd., the flagship company, is holding the strong leadership position in the pharmaceutical industry of Bangladesh since 1985 and it has been continuously in the 1st position among all national and multinational companies since 1985. Square Pharmaceuticals Ltd. is now on its way to becoming a high performance global player. SQUARE today symbolizes a name – a state of mind. But its journey to the growth and prosperity has been no bed of roses. From the
Words: 1318 - Pages: 6
move that I am sure will shake up the pharmaceutical industry, as for “Big Pharma” patents ensure a steady stream of exorbitant profits from new drugs for many years. For example, in the U.S., these patents could last 20 years from the time they are first filed, which results in drug companies being able to mark-up the cost of drugs as much as 569,000 percent higher than the cost of their actual raw materials. Working in the health industry (Health Insurance), I see how the unreasonably high drug
Words: 296 - Pages: 2
